GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » ROA %

Infinity Pharmaceuticals (Infinity Pharmaceuticals) ROA %

: -155.61% (As of Jun. 2023)
View and export this data going back to 2000. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Infinity Pharmaceuticals's annualized Net Income for the quarter that ended in Jun. 2023 was $-39.82 Mil. Infinity Pharmaceuticals's average Total Assets over the quarter that ended in Jun. 2023 was $25.59 Mil. Therefore, Infinity Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2023 was -155.61%.

The historical rank and industry rank for Infinity Pharmaceuticals's ROA % or its related term are showing as below:

INFIQ' s ROA % Range Over the Past 10 Years
Min: -99.01   Med: -45   Max: -5.81
Current: -99.01

During the past 13 years, Infinity Pharmaceuticals's highest ROA % was -5.81%. The lowest was -99.01%. And the median was -45.00%.

INFIQ's ROA % is ranked worse than
83.15% of 1555 companies
in the Biotechnology industry
Industry Median: -35.62 vs INFIQ: -99.01

Infinity Pharmaceuticals ROA % Historical Data

The historical data trend for Infinity Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.82 -86.16 -91.68 -72.94 -69.91

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.33 -75.57 -78.77 -122.55 -155.61

Competitive Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals ROA % Distribution

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's ROA % falls into.



Infinity Pharmaceuticals ROA % Calculation

Infinity Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-44.369/( (84.785+42.151)/ 2 )
=-44.369/63.468
=-69.91 %

Infinity Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2023 is calculated as:

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=-39.824/( (29.951+21.232)/ 2 )
=-39.824/25.5915
=-155.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data. ROA % is displayed in the 30-year financial page.


Infinity Pharmaceuticals  (OTCPK:INFIQ) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-39.824/25.5915
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-39.824 / 2.332)*(2.332 / 25.5915)
=Net Margin %*Asset Turnover
=-1707.72 %*0.0911
=-155.61 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Infinity Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Executives
Adelene Q Perkins director, officer: President & CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso officer: Chief Scientific Officer 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria officer: Chief Medical Officer 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch officer: EVP, CFO & CBO
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti director

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Headlines

From GuruFocus